Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting results. Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens. Topical Tenofovir delivery to the vaginal environment is complex, multivariate and non-linear; determinants relate to drug, vehicle, dosage regimen, and environment. Experimental PK methods cannot yield mechanistic understanding of this process, and have uncontrolled variability in drug sampling. Mechanistic modeling of the process could help delineate its determinants, and be a tool in design and interpretation of product...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...
Gels are one of the soft material platforms being evaluated to deliver topically acting anti-HIV dru...
Vaginal tablets are being developed as an alternative to gels as an inexpensive, discreet dosage for...
Background: Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens. To inhib...
<p>A new modality for preventing HIV transmission is emerging in the form of topical microbicides. S...
Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 inf...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
Background: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens. To inhib...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...
Gels are one of the soft material platforms being evaluated to deliver topically acting anti-HIV dru...
Vaginal tablets are being developed as an alternative to gels as an inexpensive, discreet dosage for...
Background: Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens. To inhib...
<p>A new modality for preventing HIV transmission is emerging in the form of topical microbicides. S...
Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 inf...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
Background: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens. To inhib...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...
Gels are one of the soft material platforms being evaluated to deliver topically acting anti-HIV dru...
Vaginal tablets are being developed as an alternative to gels as an inexpensive, discreet dosage for...